胰腺导管腺癌的综合基因组特征分析
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.
出版信息
Cancer Cell. 2017 Aug 14;32(2):185-203.e13. doi: 10.1016/j.ccell.2017.07.007.
Abstract
We performed integrated genomic, transcriptomic, and proteomic profiling of 150 pancreatic ductal adenocarcinoma (PDAC) specimens, including samples with characteristic low neoplastic cellularity. Deep whole-exome sequencing revealed recurrent somatic mutations in KRAS, TP53, CDKN2A, SMAD4, RNF43, ARID1A, TGFβR2, GNAS, RREB1, and PBRM1. KRAS wild-type tumors harbored alterations in other oncogenic drivers, including GNAS, BRAF, CTNNB1, and additional RAS pathway genes. A subset of tumors harbored multiple KRAS mutations, with some showing evidence of biallelic mutations. Protein profiling identified a favorable prognosis subset with low epithelial-mesenchymal transition and high MTOR pathway scores. Associations of non-coding RNAs with tumor-specific mRNA subtypes were also identified. Our integrated multi-platform analysis reveals a complex molecular landscape of PDAC and provides a roadmap for precision medicine.
摘要
我们对150份胰腺导管腺癌（PDAC）标本进行了综合基因组、转录组和蛋白质组分析，包括具有低肿瘤细胞特征的样本。深度全外显子测序揭示了KRAS、TP53、CDKN2A、SMAD4、RNF43、ARID1A、TGFβR2、GNAS、RREB1和PBRM1等基因的复发性体细胞突变。KRAS野生型肿瘤在其他致癌驱动基因中存在改变，包括GNAS、BRAF、CTNNB1和其他RAS通路基因。一部分肿瘤存在多个KRAS突变，其中一些显示出双等位基因突变的证据。蛋白质分析确定了一个预后良好的亚组，其上皮-间质转化程度低且MTOR通路得分高。还确定了非编码RNA与肿瘤特异性mRNA亚型之间的关联。我们的综合多平台分析揭示了PDAC复杂的分子格局，并为精准医学提供了路线图。
相似文献
1
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.
Cancer Cell. 2017 Aug 14;32(2):185-203.e13. doi: 10.1016/j.ccell.2017.07.007.
2
The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.
BMC Cancer. 2022 Feb 18;22(1):186. doi: 10.1186/s12885-022-09279-9.
3
Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.
Cancer Med. 2023 May;12(10):11672-11685. doi: 10.1002/cam4.5871. Epub 2023 Mar 31.
4
DNA methylation memory of pancreatic acinar-ductal metaplasia transition state altering Kras-downstream PI3K and Rho GTPase signaling in the absence of Kras mutation.
Genome Med. 2025 Mar 28;17(1):32. doi: 10.1186/s13073-025-01452-6.
5
Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild-Type Pancreatic Cancer.
Cancer Sci. 2025 Apr;116(4):1094-1106. doi: 10.1111/cas.16456. Epub 2025 Jan 20.
6
Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic ductal adenocarcinoma.
Genome Biol. 2021 Jan 4;22(1):4. doi: 10.1186/s13059-020-02222-w.
7
High overall copy number variation burden by genome-wide methylation profiling holds negative prognostic value in surgically treated pancreatic ductal adenocarcinoma.
Hum Pathol. 2023 Dec;142:68-80. doi: 10.1016/j.humpath.2023.11.002. Epub 2023 Nov 17.
8
Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array.
Mol Med Rep. 2015 Nov;12(5):7479-84. doi: 10.3892/mmr.2015.4344. Epub 2015 Sep 22.
9
Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease.
J Natl Cancer Inst. 2024 Sep 1;116(9):1429-1438. doi: 10.1093/jnci/djae095.
10
Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
Cancer. 2020 Sep 1;126(17):3939-3949. doi: 10.1002/cncr.33038. Epub 2020 Jun 23.
引用本文的文献
1
Hypoxia-induced metastatic heterogeneity in pancreatic cancer.
bioRxiv. 2025 Aug 29:2025.08.26.672389. doi: 10.1101/2025.08.26.672389.
2
Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection in Pancreatic Ductal Adenocarcinoma.
JCO Precis Oncol. 2025 Sep;9:e2500197. doi: 10.1200/PO-25-00197. Epub 2025 Sep 4.
3
Pathway-Specific Genomic Alterations in Pancreatic Cancer Across Populations at Risk.
Int J Mol Sci. 2025 Aug 8;26(16):7695. doi: 10.3390/ijms26167695.
4
Roles and Prospective Applications of Ferroptosis Suppressor Protein 1 (FSP1) in Malignant Tumor Treatment.
Curr Oncol. 2025 Aug 14;32(8):456. doi: 10.3390/curroncol32080456.
5
Molecular characterization and prognostic implications of KRAS mutations in pancreatic cancer patients: insights from multi-cohort analysis.
NPJ Precis Oncol. 2025 Aug 22;9(1):299. doi: 10.1038/s41698-025-01087-1.
6
KRAS: the Achilles' heel of pancreas cancer biology.
J Clin Invest. 2025 Aug 15;135(16). doi: 10.1172/JCI191939.
7
The impact of perioperative chemotherapy in patients with pancreatic adenosquamous carcinoma.
Surgery. 2025 Aug 13;187:109611. doi: 10.1016/j.surg.2025.109611.
8
Multi-omics whole-genome characterization of the copy number landscape of metastatic pancreatic ductal adenocarcinoma.
iScience. 2025 Jul 22;28(8):113176. doi: 10.1016/j.isci.2025.113176. eCollection 2025 Aug 15.
9
Epigenetic evolution and clinicopathological implications of distinct DNA methylation profiles in pancreatic ductal adenocarcinoma.
Sci Rep. 2025 Aug 6;15(1):28747. doi: 10.1038/s41598-025-13919-y.
10
Cannabidiol Suppresses EMT in Pancreatic Cancer via Inhibition of MALAT1 lncRNA and PI3K/Akt/mTOR Signaling Pathway.
IUBMB Life. 2025 Aug;77(8):e70042. doi: 10.1002/iub.70042.
本文引用的文献
1
Chromatin environment, transcriptional regulation, and splicing distinguish lincRNAs and mRNAs.
Genome Res. 2017 Jan;27(1):27-37. doi: 10.1101/gr.214205.116. Epub 2016 Dec 7.
2
A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns.
Nature. 2016 Oct 20;538(7625):378-382. doi: 10.1038/nature19823. Epub 2016 Oct 12.
3
IRAK1, a Target of miR-146b, Reduces Cell Aggressiveness of Human Papillary Thyroid Carcinoma.
J Clin Endocrinol Metab. 2016 Nov;101(11):4357-4366. doi: 10.1210/jc.2016-2276. Epub 2016 Aug 17.
4
GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer.
Gut. 2017 Sep;66(9):1665-1676. doi: 10.1136/gutjnl-2015-311256. Epub 2016 Jun 20.
5
Deficiency of mitochondrial modulator MCJ promotes chemoresistance in breast cancer.
JCI Insight. 2016 May 19;1(7). doi: 10.1172/jci.insight.86873.
6
The Ensembl Variant Effect Predictor.
Genome Biol. 2016 Jun 6;17(1):122. doi: 10.1186/s13059-016-0974-4.
7
Epigenetic identification of ZNF545 as a functional tumor suppressor in multiple myeloma via activation of p53 signaling pathway.
Biochem Biophys Res Commun. 2016 Jun 10;474(4):660-666. doi: 10.1016/j.bbrc.2016.04.146. Epub 2016 May 2.
8
NPInter v3.0: an upgraded database of noncoding RNA-associated interactions.
Database (Oxford). 2016 Apr 17;2016. doi: 10.1093/database/baw057. Print 2016.
9
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2.
Cancer Cell. 2016 Apr 11;29(4):477-493. doi: 10.1016/j.ccell.2016.02.010. Epub 2016 Mar 17.
10
Clinical prognostic value of DNA methylation in hepatoblastoma: Four novel tumor suppressor candidates.
Cancer Sci. 2016 Jun;107(6):812-9. doi: 10.1111/cas.12928. Epub 2016 Apr 27.
Zotero 插件